Amgen Stock Trades 18.3% Above Intrinsic Value Amid Dividend Attraction

Amgen Inc (NASDAQ: AMGN) recently announced compelling results from the Phase 3 VESALIUS-CV trial, showing that its cholesterol-lowering drug Repatha reduced mortality risk by 20% in high-risk adults without prior heart attack or stroke.

The news arrives amid ongoing investor interest in AMGN's dividend profile and valuation. The company offers a dividend yield of 2.3% with a payout ratio of 44%, supported by a healthy 3-year dividend growth rate of 7.1%, indicating sustainable income potential.

However, Amgen is currently trading 18.3% above its GF Value™ intrinsic estimate, according to GuruFocus' proprietary valuation metric. The company's strong profitability and growth fundamentals provide some justification for the elevated price, but investors should be cautious due to a moderate financial strength score and insider selling activity.